

# Our Future Healthcare Innovations for the World

July 4th (Wed) 2018, 17:00-19:00

Academic Hall, Molecular Life Innovation Tower

## Agenda

Moderator: Dr. Yuichi Tei/Ung-il Chung  
Professor, Graduate School of Engineering / Graduate School of Medicine,  
The University of Tokyo

---

17:00-17:20 **Dx Innovation in the Era of Precision Medicine and Big Data: Opportunities and Challenges**

*Dr. Yiu-Lian Fong*

*Global Head, Scientific Innovation, Diagnostics, Johnson & Johnson Innovation*

Q&A

17:30-17:50 **Supercomputing and Artificial Intelligence Break Cancer Genome Big Data**

*Dr. Seiya Imoto*

*Professor, Health Intelligence Center, Institute of Medical Science,  
The University of Tokyo*

Q&A

18:00-18:20 **The Innovative Medicines Initiative: Building a Public Private Partnership to Accelerate Innovation**

*Dr. Pierre Meulien*

*Executive Director, IMI (Innovative Medicines Initiative)*

Q&A

18:30-18:50 **Japan Public-Private Partnership Experiences in Alzheimer's Disease Prevention**

*Dr. Takeshi Iwatsubo*

*Professor, Department of Neuropathology, Graduate School of Medicine,  
The University of Tokyo*

Q&A

Introduction of Open Innovation Initiative by Johnson & Johnson

Symposium will be held on 31 October 2018, 13:00- at Ito Hall, the University of Tokyo!  
Further details will be announced later.

シンポジウム開催決定！ 2018年10月31日(水) 13:00～ 東京大学 伊藤謝恩ホール  
詳細は追ってお知らせいたします。

### Dr. Yiu-Lian Fong

Yiu-Lian is the Global Head for Diagnostic Innovation, Research and Early Development at Johnson & Johnson Innovation. Yiu-Lian has global responsibility for identifying, assessing and accelerating the development of breakthrough diagnostic technologies and solutions to help drive precision medicine and Johnson & Johnson's World Without Disease initiative. Prior to joining Johnson & Johnson Innovation, Yiu-Lian was the Divisional Vice President for R&D at Abbott Molecular. Previously, she was the Executive Director of Molecular Diagnostics and Companion Diagnostics Development at Novartis Oncology. Yiu-Lian received her M.S. in Life Sciences from The National Tsing Hua University in Taiwan, and her MBA from the University of Massachusetts, Amherst. She earned her Ph.D. in Molecular Physiology and Biophysics from Vanderbilt University and was a post graduate fellow at Johns Hopkins University. Yiu-Lian also has 25 publications in peer review journals and several issued patent applications.

---



### Dr. Seiya Imoto

Seiya Imoto received the BS, MS, and PhD degrees in mathematics from Kyushu University, Japan, in 1996, 1998, and 2001, respectively. He is currently director and professor of Health Intelligence Center, the Institute of Medical Science, the University of Tokyo. He joined the Institute of Medical Science, the University of Tokyo in 2001. He is also an advisor (medical statistics) of Ministry of Health, Labour and Welfare. His current research interests cover statistical analysis of high-dimensional data by Bayesian approach, biomedical information analysis, next generation sequence data analysis, immuno-genomics, artificial intelligence and meta-genome data analysis.

---



### Dr. Pierre Meulien

Pierre Meulien is Executive Director of the Innovative Medicines Initiative (IMI), a €5 billion public-private partnership between the European Union and the European pharmaceutical industry. He is responsible for the overall management of our programme, which is working to improve and accelerate the entire medicines development process by facilitating collaboration between the key players involved in health research, including universities, pharmaceutical and other companies, patient organisations, and medicines regulators. Dr Meulien joined IMI in September 2015. From 2010 to 2015, Dr Meulien was President and CEO of Genome Canada. Prior to that from 2007 to 2010, he was Chief Scientific Officer for Genome British Columbia. From 2002 to 2007, Dr Meulien served as founding CEO of the Dublin Molecular Medicine Centre (now Molecular Medicine Ireland). Dr Meulien also worked in the private sector with the French biotechnology company Transgene, and with Aventis Pasteur (now Sanofi Pasteur). He has a PhD in molecular biology from the University of Edinburgh and carried out a post-doctoral fellowship at the Institut Pasteur in Paris. Dr Meulien has Irish nationality.

---



### Dr. Takeshi Iwatsubo

Takeshi Iwatsubo is a Professor of Neuropathology at Graduate School of Medicine, the University of Tokyo. He was graduated from School of Medicine, the University of Tokyo in 1984. Since being PI at School of Pharmaceutical Sciences, the University of Tokyo, on 1992, he has contributed to studies of human neurodegenerative disorders, and elucidated molecular mechanisms on formation of senile plaque amyloid and Lewy bodies. On the clinical front, he has been the PI of Japanese AD Neuroimaging Initiative (J-ADNI) project, aiming at establishing standard surrogate markers for clinical trials of disease-modifying therapies for AD. Currently he serves as the PI of A4 study in Japan, an anti-A $\beta$  intervention study on preclinical AD.

